Overview
Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN).
Cohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clBCI) to see if can help to prevent pain due to CIPN.
Description
Primary Objectives:
Objective 1 (Primary Objective): to examine preliminary baseline and serial electrophysiological markers associated with the onset and development of CIPN by tracking brain activity and CIPN symptoms throughout chemotherapy treatment.
Secondary Objectives:
Objective 2 (Secondary Objective): To preliminarily evaluate whether a clBCI program can regulate changes in EEG that are associated with CIPN while participants are undergoing chemotherapy.
Exploratory Objective: Explore whether there are associations between change in brain function and subjective report of CIPN.
Eligibility
Inclusion criteria:
Objective 1 Inclusion criteria
- Participants must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
- ECOG Performance Status of 0-2;
- Willing to come to MD Anderson for the imaging sessions.
- Are 18 years of age or above.
- Have a diagnosis of breast cancer.
- will receive chemotherapy including doxorubicin, cyclophosphamide, docetaxel, or paclitaxel;
Objective 2 Inclusion criteria:
- Inclusion criteria: Identical to Objective 1 and are willing to participate in the therapy sessions at their homes.
Exclusion Criteria
Objective 1 Exclusion criteria:
- Participants who are taking any antipsychotic medications.
- With active CNS disease, such as clinically evident metastases or leptomeningeal disease, dementia, or encephalopathy.
- Have ever been diagnosed with bipolar disorder or schizophrenia.
- Known, previously diagnosed peripheral neuropathy from causes other than chemotherapy; and
- A history of head injury or who have known seizure activity, or with a prior history of chemotherapy.
- Patients who will be administered ddAC->T.
Objective 2 Exclusion criteria
- Same exclusion criteria as in Objective1. Medication usage will be tracked for patients in all groups. Once prescribed, participants must remain on a stable course of medications throughout the course of chemotherapy.